Asia Pacific Cardiac Marker Testing Market Size, Share, Trends and Overview 2021

Posted by Olive David on December 4th, 2017

Asia Pacific Cardiac Marker Testing Market Size is expected to grow at 11.7% CAGR from 2016 to 2021 and it is projected that the Asia-Pacific market was valued at USD 0.37 billion in 2016 and is anticipated to reach USD 0.64 billion by 2021.

Cardiac Bio-Marker Diagnostic Test market includes the diagnostic tests used to measure the concentration of proteins, also known as biomarkers that indicate the occurrence and phase of cardiovascular disease (CVD). Cardiac biomarkers evaluate the heart function and aid in identifying the complexity and severity of procedures further required to treat the cardiovascular disease. The primary indications for cardiovascular diseases are Acute Coronary Syndrome (ACS) which include Angina Pectoris (AP) and Acute Myocardial Infraction (AMI) Congestive Heart Failure (CHF), Peripheral Artery Disease (PAD) and others.  The major causes of CVD are High Blood Pressure, smoking, diabetes, inadequate exercise, stress, unhealthy diet, alcoholism, obesity and high blood cholesterol. More than half of the cardiovascular diseases can be cured if diagnosed at the right time.

Full report at: http://www.marketdataforecast.com/market-reports/asia-pacific-cardiac-marker-testing-market-4986/

Factor such as increase in the incidence and occurrences of cardiovascular diseases is among the main factors driving the market growth.  Furthermore, a number of factors such as growing instances of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse schemes are expected to hinder the growth of the market.

The Asia Pacific Cardiac Marker Testing Market segmentation by Type, Product, Disease, and Testing. On the basis of Type, it is segmented into Troponin I & T, CK-MB, Myoglobin, BNP, and hsCRP. The creatine kinase segment is further segmented into M & B subunits: CK-MM, CK-MB, and CK-BB. The troponin cardiac biomarkers segment held the largest share of this market segment. On the basis of Product, it is segmented into Reagent and Instrument. The instrument segment is furtherer segmented into Chemiluminescence, Immunofluorescence, Immunochromatography, and ELISA. On the basis of Disease, it is segmented into Acute Coronary Syndrome, Myocardial Infarction, and Congestive Heart Failure. ACS is expected to be the fasting growing segment driven. Myocardial infarction is anticipated to be the second fastest growing segment. On the basis of Testing, it is segmented into Lab and POC. The laboratory testing segment is expected to hold the largest share of this market segment, while the point-of-care testing segment is expected to register the highest growth rate in this market segment.

Request sample: http://www.marketdataforecast.com/market-reports/asia-pacific-cardiac-marker-testing-market-4986/request-sample

On the basis of geography, the market is analyzed under various regions namely India, China, Japan, Australia and South Korea. Asia-Pacific market is expected to register the highest growth. Emerging markets, including India and China, have become attractive destinations for companies engaged in the development and marketing of cardiac biomarkers. Rising prevalence and incidence of cardiovascular diseases is among the major driving factors for the growth of this market in China and India. For instance, annual cardiovascular events in China were projected to increase by more than 50% from 2010 to 2030. China has one of the highest CVD death rates in the world and it is estimated that one in 5 adults in China has a cardiovascular disease. In addition to this, public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors propelling the demand for cardiac biomarkers in the emerging markets.

Some of the companies dominating the market are bioMérieux SA, LSI Medience Corporation, Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere, Inc., Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.

About Market Data Forecast:

The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com

Contact:

Abhishek Shukla

Sales Manager (International Business Development)

Market Data Forecast

Direct Line: +1-888-702-9626

Mobile: +91 998 555 0206

Mail: abhishek@marketdataforecast.com